Everolimus for subependymal giant cell astrocytoma: 5‐year final analysis

Abstract

Everolimus continues to demonstrate a sustained effect on SEGA tumor reduction over ≥5 years of treatment. Everolimus remained well-tolerated, and no new safety concerns were noted.